Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 23, 2010, Pages 10655-10660

  Bianchi, Elisabetta ^a   Joyce, Joseph G ^a   Miller, Michael D ^a   Finnefrock, Adam C ^a   Liang, Xiaoping ^a   Finotto, Marco ^a   Ingallinella, Paolo ^a   McKenna, Philip ^a   Citron, Michael ^a   Ottinger, Elizabeth ^a   Hepler, Robert W ^a   Hrin, Renee ^a   Nahas, Deborah ^a   Wu, Chengwei ^a   Montefiori, David ^b   Shiver, John W ^a   Pessi, Antonello ^a   Kime, Peter S ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Coiled coil; Membrane fusion; Mimotope; Vaccine

Indexed keywords

GLYCOPROTEIN GP 41; IMMUNOGLOBULIN G; IZN17; IZN36; NEUTRALIZING ANTIBODY; PEPTIDOMIMETIC AGENT; TRIMERIC PEPTIDOMIMETIC AGENT CCIPN17; TRIMERIC PEPTIDOMIMETIC AGENT CCIPN36; TRIMERIC PEPTIDOMIMETIC AGENT CCIZN17; TRIMERIC PEPTIDOMIMETIC AGENT CCIZN36; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; GUINEA PIG; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYDROPHOBICITY; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SEROLOGY; VACCINATION; VIRUS ENTRY; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS REPLICATION; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; BIOMIMETIC MATERIALS; GUINEA PIGS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV-1; IMMUNE SERA; MOLECULAR SEQUENCE DATA; PEPTIDES; RABBITS; VACCINATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; SIMIAE;

EID: 77953752637     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1004261107     Document Type: Article

References (40)

1. Zwick MB, Burton DR (2007) HIV-1 neutralization: Mechanisms and relevance to vaccine design. Curr HIV Res 5:608-624. (Pubitemid 351210995)
2. Barouch DH (2008) Challenges inthe development of anHIV-1 vaccine. Nature 455:613-619.
3. Karlsson Hedestam GB, et al. (2008) The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6:143-155.
4. Walker LM, et al.; Protocol G Principal Investigators (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
5. Rerks-Ngarm S, et al.; MOPH-TAVEG Investigators (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361:2209-2220.
6. Naider F, Anglister J (2009) Peptides in the treatment of AIDS. Curr Opin Struct Biol 19:473-482.
7. Lazzarin A, et al.; TORO 2 Study Group (2003) Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 348:2186-2195.
8. Eckert DM, Kim PS (2001) Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 70:777-810.
9. Colman PM, Lawrence MC (2003) The structural biology of type I viral membrane fusion. Nat Rev Mol Cell Biol 4:309-319. (Pubitemid 36383957)
10. Lu M, Blacklow SC, Kim PS (1995) A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 2:1075-1082.
11. Chan DC, Fass D, Berger JM, Kim PS (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263-273.
12. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC (1997) Atomic structure of the ectodomain from HIV-1 gp41. Nature 387:426-430.
13. Tan K, Liu J, Wang J, Shen S, Lu M (1997) Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci USA 94:12303-12308.
14. Caffrey M, et al. (1998) Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41. EMBO J 17:4572-4584.
15. Eckert DM, Malashkevich VN, Hong LH, Carr PA, Kim PS (1999) Inhibiting HIV-1 entry: Discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99:103-115.
16. Eckert DM, Kim PS (2001) Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc Natl Acad Sci USA 98:11187-11192.
17. Root MJ, Kay MS, Kim PS (2001) Protein design of an HIV-1 entry inhibitor. Science 291:884-888. (Pubitemid 32120761)
18. Miller MD, et al. (2005) A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci USA 102:14759-14764.
19. Luftig MA, et al. (2006) Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. Nat Struct Mol Biol 13:740-747.
20. Chan DC, Chutkowski CT, Kim PS (1998) Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci USA 95:15613-15617.
21. Frey G, et al. (2006) Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion. Proc Natl Acad Sci USA 103:13938-13943. (Pubitemid 44452961)
22. Ferrer M, et al. (1999) Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat Struct Biol 6:953-960. (Pubitemid 29463310)
23. Bianchi E, et al. (2005) Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection. Proc Natl Acad Sci USA 102:12903-12908.
24. Louis JM, Bewley CA, Gustchina E, Aniana A, Clore GM (2005) Characterization and HIV-1 fusion inhibitory properties of monoclonal Fabs obtained from a human non-immune phage library selected against diverse epitopes of the ectodomain of HIV-1 gp41. J Mol Biol 353:945-951. (Pubitemid 41503263)
25. Gustchina E, Louis JM, Lam SN, Bewley CA, Clore GM (2007) A monoclonal Fab derived froma human nonimmune phage library reveals a new epitope on gp41 and neutralizes diverse human immunodeficiency virus type 1 strains. J Virol 81:12946-12953. (Pubitemid 350156932)
26. Nelson JD, et al. (2008) Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. Virology 377:170-183.
27. Louis JM, Nesheiwat I, Chang LC, Clore GM, Bewley CA (2003) Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against themare potent inhibitors of HIV envelope-mediated cell fusion. J Biol Chem 278:20278-20285. (Pubitemid 36799226)
28. Bianchi E, et al. (2008) Peptides for Youth, Proceedings of the 20th American Peptide Symposium, eds Escher E, Lubell WD, Del Valle S (Springer, New York), pp 359-360.
29. Promadej-Lanier N, et al. (2008) Systemic and mucosal immunological responses during repeated mucosal SHIV(162P3) challenges prior to and following infection in pigtailed macaques. Virology 375:492-503.
30. Hessell AJ, et al. (2007) Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449:101-104.
31. Hessell AJ, et al. (2009) Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog, 10.1371/journal.ppat.1000433.
32. Seaman MS, et al. (2007) Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens. Virology 367:175-186.
33. Nishimura Y, et al. (2002) Determination of a statistically valid neutralization titer in plasmathat confers protection against simian-humanimmunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J Virol 76:2123-2130.
34. Mascola JR, et al. (2000) Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6:207-210.
35. Parren PWHI, et al. (2001) Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 75:8340-8347.
36. Regoes RR, Longini IM, Feinberg MB, Staprans SI (2005) Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges. PLoS Med, 10.1371/journal.pmed.0020249.
37. Johnson PR, et al. (2009)Vector-mediatedgenetransferengenders long-livedneutralizing activity and protection against SIV infection in monkeys. Nat Med 15:901-906.
38. Hessell AJ, et al. (2009) Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 15:951-954.
39. Hamburger AE, Kim S, Welch BD, Kay MS (2005) Steric accessibility of the HIV-1 gp41 N-trimer region. J Biol Chem 280:12567-12572. (Pubitemid 40491074)
40. Steger HK, Root MJ (2006) Kinetic dependence to HIV-1 entry inhibition. J Biol Chem 281:25813-25821.